BAY 59-7939: Phase IIb data

In a double-blind, Phase IIb trial in 548 evaluable patients undergoing elective total hip replacement, BAY 59-7939 twice-daily met all primary endpoints compared with enoxaparin. VE rates were 15%, 1...